Marshall & Sullivan’s Amgen AMGN Stock Holding History

Marshall & Sullivan’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17	Closed	-$4K	–	38
2022 Q2	$4K	Buy	+17	New	+$4.17K	﹤0.01%	84

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall & Sullivan's AMGN Position: Q3 2022 in Review

Marshall & Sullivan sold out of Amgen (AMGN) in Q3 2022, closing a stake of 17 shares — an estimated $4K sold.

Marshall & Sullivan first reported a position in AMGN in Q2 2022 and held it in 1 quarter. The position peaked at $4K in Q2 2022. 2,322 funds tracked by Wall St. Rank hold AMGN as of Q3 2022.

Marshall & Sullivan reported no remaining Amgen position as of Q3 2022 after selling out during the quarter.
Marshall & Sullivan sold 17 Amgen shares in Q3 2022, an estimated $4K.
Marshall & Sullivan first reported a position in Amgen in Q2 2022 and held it in 1 quarter.
Marshall & Sullivan's Amgen position peaked at $4K in Q2 2022.
2,322 funds tracked by Wall St. Rank held Amgen as of Q3 2022.

Based on Marshall & Sullivan's 13F filing for Q3 2022, filed 28 Oct 2022.